Why Did Polyrizon Stock Soar Pre-Market Today?

• The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.
• Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.
• The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.

Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.

Following the update, Polyrizon’s stock traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes. 

Milestone Achievement

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.

"The process validated our manufacturing strategy.” 

-Tomer Izraeli, CEO, Polyrizon

 

“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."

Preparing For Clinical Trials

The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.

The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture & Contain (C&C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens. 

PLRZ stock has lost over 99% in the last 12 months. 

Also See: MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on